Short Interest in Celularity Inc. (NASDAQ:CELU) Grows By 9.3%

Celularity Inc. (NASDAQ:CELU) was the recipient of a significant increase in short interest in October. As of October 31st, there was short interest totalling 743,700 shares, an increase of 9.3% from the October 15th total of 680,500 shares. Approximately 6.9% of the company’s stock are short sold. Based on an average daily volume of 876,800 shares, the short-interest ratio is currently 0.8 days.

Celularity Stock Performance

CELU stock traded up $0.36 during trading on Monday, hitting $2.82. 479,336 shares of the company’s stock traded hands, compared to its average volume of 374,318. Celularity has a 1 year low of $1.30 and a 1 year high of $7.97. The business has a fifty day simple moving average of $2.55 and a two-hundred day simple moving average of $2.88.

Celularity (NASDAQ:CELU) last announced its quarterly earnings results on Wednesday, October 16th. The company reported ($1.03) earnings per share (EPS) for the quarter. The company had revenue of $14.68 million during the quarter. Celularity had a negative net margin of 264.30% and a negative return on equity of 92.48%.

Hedge Funds Weigh In On Celularity

A hedge fund recently bought a new stake in Celularity stock. Keynote Financial Services LLC acquired a new position in Celularity Inc. (NASDAQ:CELU) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 15,566 shares of the company’s stock, valued at approximately $81,000. Keynote Financial Services LLC owned about 0.08% of Celularity as of its most recent SEC filing. 19.02% of the stock is owned by institutional investors and hedge funds.

Celularity Company Profile

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.